Merck Inc announced that the FDA has approved an expanded indication for Ervebo, which is now indicated for the prevention of disease caused by Zaire ebolavirus in individuals… read more.
Between 7% and 15% of people in North America, between 5% and 9% of people in Europe, and between 1% and 5% of people in Asia suffer from… read more.
Skin, the largest organ of the human body, is home to a vast array of bacteria, fungi, and viruses – microorganisms that compose the skin microbiota. Among other… read more.
Abbott is initiating a US market withdrawal for the Trifecta family of valves and will be removing the limited remaining inventory from the field. On February 27, 2023,… read more.
Despite advances in surgery and chemotherapy, survival of people with certain types of ovarian cancer has not significantly changed in decades. That has meant that some ovarian cancer… read more.
Amid widely differing capacities of available menstrual hygiene products, a menstrual disc—similar in shape to a diaphragm—may be best for dealing with heavy monthly blood flow as well… read more.
Sage Therapeutics, Inc .and Biogen Inc. announced the FDA approved Zurzuvae (zuranolone) 50 mg for adults with postpartum depression (PPD). Zurzuvae is the first and only oral, once-daily,… read more.
A study of more than 50,000 women found that continued breast cancer screening after age 70 was associated with a greater incidence of cancer that likely would not… read more.
Galapagos revealed that it is weighing up all options for its only approved product, the JAK inhibitor Jyseleca. Galapagos has disclosed its financials for the first half 2023… read more.
As little as 25 minutes a day of slow walking seems to be enough to counter the detrimental physical effects of bedrest on older hospital patients, finds a… read more.
Smoking in pregnancy can harm developing babies, especially their growth . Current guidelines recommend that pregnant smokers who find quitting difficult should be provided with nicotine replacements products and… read more.
Taiho Pharmaceutical announced that its partner Servier, has won European regulatory approval for Lonsurf (trifluridine + tipiracil) in combination with bevacizumab for the third-line treatment of metastatic colorectal… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
